PA-824 (BioDeep_00000675234)
代谢物信息卡片
Pretomanid
化学式: C14H12F3N3O5 (359.0729)
中文名称: Pretomanid
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1C(COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
InChI: InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1
描述信息
J - Antiinfectives for systemic use > J04 - Antimycobacterials > J04A - Drugs for treatment of tuberculosis
C254 - Anti-Infective Agent > C52588 - Antibacterial Agent > C280 - Antitubercular Agent
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D10722
- PubChem: 456199
- DrugBank: DB05154
- ChEMBL: CHEMBL227875
- CAS: 187235-37-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Catherine Berry, Philipp du Cros, Katherine Fielding, Suzanne Gajewski, Emil Kazounis, Timothy D McHugh, Corinne Merle, Ilaria Motta, David A J Moore, Bern-Thomas Nyang'wa. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Trials.
2022 Jun; 23(1):484. doi:
10.1186/s13063-022-06331-8. [PMID: 35698158] - Yue Liu, Yan Tan, Gang Wei, Zhifei Lu, Yazhou Liu, Bo Yang, Ai-Min Hui, Kexin Li. Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study.
Pulmonary pharmacology & therapeutics.
2022 06; 73-74(?):102132. doi:
10.1016/j.pupt.2022.102132. [PMID: 35595003] - K Boekelheide, M Olugbosi, J Nedelman, D Everitt, E Smith, M Betteridge, E Sun, M Spigelman. Male reproductive hormones in patients treated with pretomanid.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
2022 Jun; 26(6):558-565. doi:
10.5588/ijtld.21.0654. [PMID: 35650700] - Andisiwe Malo, Tracy Kellermann, Elisa H Ignatius, Kelly E Dooley, Rodney Dawson, Anton Joubert, Jennifer Norman, Sandra Castel, Lubbe Wiesner. A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients.
Journal of pharmaceutical and biomedical analysis.
2021 Feb; 195(?):113885. doi:
10.1016/j.jpba.2020.113885. [PMID: 33406472] - Yanlin Jian, He Eun Forbes, Fabian Hulpia, Martijn D P Risseeuw, Guy Caljon, Hélène Munier-Lehmann, Helena I M Boshoff, Serge Van Calenbergh. 2-((3,5-Dinitrobenzyl)thio)quinazolinones: Potent Antimycobacterial Agents Activated by Deazaflavin (F420)-Dependent Nitroreductase (Ddn).
Journal of medicinal chemistry.
2021 01; 64(1):440-457. doi:
10.1021/acs.jmedchem.0c01374. [PMID: 33347317] - Hanbin Li, David H Salinger, Daniel Everitt, Mengchun Li, Angelo Del Parigi, Carl Mendel, Jerry R Nedelman. Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Antimicrobial agents and chemotherapy.
2019 10; 63(10):. doi:
10.1128/aac.00445-19. [PMID: 31358590] - Clément Ghiazza, Thierry Billard, Callum Dickson, Anis Tlili, Christian M Gampe. Chalcogen OCF3 Isosteres Modulate Drug Properties without Introducing Inherent Liabilities.
ChemMedChem.
2019 09; 14(17):1586-1589. doi:
10.1002/cmdc.201900452. [PMID: 31364270] - Michael A Lyons. Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.
Antimicrobial agents and chemotherapy.
2018 07; 62(7):. doi:
10.1128/aac.02359-17. [PMID: 29661865] - Diana Angelica Aguilar-Ayala, Margo Cnockaert, Peter Vandamme, Juan Carlos Palomino, Anandi Martin, Jorge Gonzalez-Y-Merchand. Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions.
Journal of medical microbiology.
2018 Mar; 67(3):282-285. doi:
10.1099/jmm.0.000681. [PMID: 29458544] - Gurleen Kour, Parvinder Pal Singh, Asha Bhagat, Zabeer Ahmed. Biopharmaceutic parameters, pharmacokinetics, transport and CYP-mediated drug interactions of IIIM-017: A novel nitroimidazooxazole analogue with anti-tuberculosis activity.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2017 Aug; 106(?):71-78. doi:
10.1016/j.ejps.2017.05.053. [PMID: 28552479] - Dominika Bratkowska, Adeola Shobo, Sanil Singh, Linda A Bester, Hendrik G Kruger, Glenn E M Maguire, Thavendran Govender. Determination of the antitubercular drug PA-824 in rat plasma, lung and brain tissues by liquid chromatography tandem mass spectrometry: application to a pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2015 Apr; 988(?):187-94. doi:
10.1016/j.jchromb.2015.02.041. [PMID: 25796075] - Kelly E Dooley, Anne F Luetkemeyer, Jeong-Gun Park, Reena Allen, Yoninah Cramer, Stephen Murray, Deborah Sutherland, Francesca Aweeka, Susan L Koletar, Florence Marzan, Jing Bao, Rada Savic, David W Haas. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
Antimicrobial agents and chemotherapy.
2014 Sep; 58(9):5245-52. doi:
10.1128/aac.03332-14. [PMID: 24957823] - Libin Wang, Yue Xu, Li Liang, Chunyan Diao, Xueying Liu, Jianchun Zhang, Shengyong Zhang. LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2014 Aug; 97(?):1-8. doi:
10.1016/j.jpba.2014.03.046. [PMID: 24798753] - Suresh B Lakshminarayana, Helena I M Boshoff, Joseph Cherian, Sindhu Ravindran, Anne Goh, Jan Jiricek, Mahesh Nanjundappa, Amit Nayyar, Meera Gurumurthy, Ramandeep Singh, Thomas Dick, Francesca Blasco, Clifton E Barry, Paul C Ho, Ujjini H Manjunatha. Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis.
PloS one.
2014; 9(8):e105222. doi:
10.1371/journal.pone.0105222. [PMID: 25141257] - Oluseye K Onajole, Marco Pieroni, Suresh K Tipparaju, Shichun Lun, Jozef Stec, Gang Chen, Hendra Gunosewoyo, Haidan Guo, Nicole C Ammerman, William R Bishai, Alan P Kozikowski. Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
Journal of medicinal chemistry.
2013 May; 56(10):4093-103. doi:
10.1021/jm4003878. [PMID: 23611124] - Sumandeep K Gill, Hao Xu, Paul D Kirchhoff, Tomasz Cierpicki, Anjanette J Turbiak, Baojie Wan, Nan Zhang, Kuan-Wei Peng, Scott G Franzblau, George A Garcia, H D Hollis Showalter. Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases.
Journal of medicinal chemistry.
2012 Apr; 55(8):3814-26. doi:
10.1021/jm201716n. [PMID: 22452568] - Silke Feuerriegel, Claudio U Köser, Davide Baù, Sabine Rüsch-Gerdes, David K Summers, John A C Archer, Marc A Marti-Renom, Stefan Niemann. Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824.
Antimicrobial agents and chemotherapy.
2011 Dec; 55(12):5718-22. doi:
10.1128/aac.05500-11. [PMID: 21930879] - Andreas H Diacon, Rodney Dawson, Madeleine Hanekom, Kim Narunsky, Stefan J Maritz, Amour Venter, Peter R Donald, Christo van Niekerk, Karl Whitney, Doris J Rouse, Martino W Laurenzi, Ann M Ginsberg, Melvin K Spigelman. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.
Antimicrobial agents and chemotherapy.
2010 Aug; 54(8):3402-7. doi:
10.1128/aac.01354-09. [PMID: 20498324] - Ann M Ginsberg, Martino W Laurenzi, Doris J Rouse, Karl D Whitney, Mel K Spigelman. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects.
Antimicrobial agents and chemotherapy.
2009 Sep; 53(9):3726-33. doi:
10.1128/aac.00112-09. [PMID: 19528286] - Ann M Ginsberg, Martino W Laurenzi, Doris J Rouse, Karl D Whitney, Melvin K Spigelman. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects.
Antimicrobial agents and chemotherapy.
2009 Sep; 53(9):3720-5. doi:
10.1128/aac.00106-09. [PMID: 19528280] - Y Hu, A R M Coates, D A Mitchison. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
2008 Jan; 12(1):69-73. doi:
NULL. [PMID: 18173880] - C K Stover, P Warrener, D R VanDevanter, D R Sherman, T M Arain, M H Langhorne, S W Anderson, J A Towell, Y Yuan, D N McMurray, B N Kreiswirth, C E Barry, W R Baker. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
Nature.
2000 Jun; 405(6789):962-6. doi:
10.1038/35016103. [PMID: 10879539]
